According to this latter work, NSCLC patients with high expression of the enzyme might be able to obtain more benefits from adjuvant chemotherapy than those with low expression, which emphasizes the predictive importance of TOP2A for such patients[26]. The gene discussed is TOP2A; the disease is non-small cell lung carcinoma.